Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Laigaard, J, Sørensen, T, Placing, S, Holck, P, Fröhlich, C, Wøjdemann, KR, Sundberg, K, Shalmi, A-C, Tabor, A, Nørgaard-Pedersen, B, Ottesen, B, Christiansen, M & Wewer, UM 2005, 'Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia', Obstetrics and Gynecology, vol. 106, no. 1, pp. 144-9. https://doi.org/10.1097/01.AOG.0000165829.65319.65

APA

Laigaard, J., Sørensen, T., Placing, S., Holck, P., Fröhlich, C., Wøjdemann, K. R., Sundberg, K., Shalmi, A-C., Tabor, A., Nørgaard-Pedersen, B., Ottesen, B., Christiansen, M., & Wewer, U. M. (2005). Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstetrics and Gynecology, 106(1), 144-9. https://doi.org/10.1097/01.AOG.0000165829.65319.65

CBE

Laigaard J, Sørensen T, Placing S, Holck P, Fröhlich C, Wøjdemann KR, Sundberg K, Shalmi A-C, Tabor A, Nørgaard-Pedersen B, Ottesen B, Christiansen M, Wewer UM. 2005. Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstetrics and Gynecology. 106(1):144-9. https://doi.org/10.1097/01.AOG.0000165829.65319.65

MLA

Vancouver

Author

Laigaard, Jennie ; Sørensen, Tina ; Placing, Sophie ; Holck, Peter ; Fröhlich, Camilla ; Wøjdemann, Karen R ; Sundberg, Karin ; Shalmi, Anne-Cathrine ; Tabor, Ann ; Nørgaard-Pedersen, Bent ; Ottesen, Bent ; Christiansen, Michael ; Wewer, Ulla M. / Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. In: Obstetrics and Gynecology. 2005 ; Vol. 106, No. 1. pp. 144-9.

Bibtex

@article{91b0178953ba43118f6bdb7b6456f636,
title = "Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia",
abstract = "OBJECTIVES: The secreted form of ADAM12 is a metalloprotease that may be involved in placental and fetal growth. We examined whether the concentration of ADAM12 in first-trimester maternal serum could be used as a marker for preeclampsia.METHODS: We developed a semiautomated, time-resolved, immunofluorometric assay for the quantification of ADAM12 in serum. The assay detected ADAM12 in a range of 78-1248 microg/L. Serum samples derived from women in the first trimester of a normal pregnancy (n = 324) and from women who later developed preeclampsia during pregnancy (n = 160) were obtained from the First Trimester Copenhagen Study. ADAM12 levels were assayed in these serum samples. Serum levels of ADAM12 were converted to multiples of the median (MoM) after log-linear regression of concentration versus gestational age.RESULTS: Serum ADAM12 levels in women who developed preeclampsia during pregnancy had a mean log MoM of -0.066, which was significantly lower than the mean log MoM of -0.001 for ADAM12 levels observed in serum samples from women with normal pregnancy (P = .008). The mean log MoM was even lower in serum derived from preeclamptic women whose infant's weight at birth was less than 2,500 g (n = 27, mean log MoM of -0.120, P = .053).CONCLUSION: The maternal serum levels of ADAM12 are significantly lower during the first trimester in women who later develop preeclampsia during pregnancy when compared with levels in women with normal pregnancies. Because the secreted form of ADAM12 cleaves insulin-like growth factor binding protein (IGFBP)-3 and IGFBP-5, the IGF axis may play a role in preeclampsia. ADAM12 may be a useful early marker for preeclampsia.LEVEL OF EVIDENCE: II-2.",
keywords = "Adult, Biomarkers, Case-Control Studies, Disintegrins, Female, Fluorescent Antibody Technique, Humans, Metalloproteases, Pre-Eclampsia, Predictive Value of Tests, Pregnancy, Pregnancy Trimester, First, Probability, Reference Values, Risk Factors, Sampling Studies, Sensitivity and Specificity, Comparative Study, Journal Article, Research Support, U.S. Gov't, Non-P.H.S.",
author = "Jennie Laigaard and Tina S{\o}rensen and Sophie Placing and Peter Holck and Camilla Fr{\"o}hlich and W{\o}jdemann, {Karen R} and Karin Sundberg and Anne-Cathrine Shalmi and Ann Tabor and Bent N{\o}rgaard-Pedersen and Bent Ottesen and Michael Christiansen and Wewer, {Ulla M.}",
year = "2005",
month = jul,
doi = "10.1097/01.AOG.0000165829.65319.65",
language = "English",
volume = "106",
pages = "144--9",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams & Wilkins",
number = "1",

}

RIS

TY - JOUR

T1 - Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia

AU - Laigaard, Jennie

AU - Sørensen, Tina

AU - Placing, Sophie

AU - Holck, Peter

AU - Fröhlich, Camilla

AU - Wøjdemann, Karen R

AU - Sundberg, Karin

AU - Shalmi, Anne-Cathrine

AU - Tabor, Ann

AU - Nørgaard-Pedersen, Bent

AU - Ottesen, Bent

AU - Christiansen, Michael

AU - Wewer, Ulla M.

PY - 2005/7

Y1 - 2005/7

N2 - OBJECTIVES: The secreted form of ADAM12 is a metalloprotease that may be involved in placental and fetal growth. We examined whether the concentration of ADAM12 in first-trimester maternal serum could be used as a marker for preeclampsia.METHODS: We developed a semiautomated, time-resolved, immunofluorometric assay for the quantification of ADAM12 in serum. The assay detected ADAM12 in a range of 78-1248 microg/L. Serum samples derived from women in the first trimester of a normal pregnancy (n = 324) and from women who later developed preeclampsia during pregnancy (n = 160) were obtained from the First Trimester Copenhagen Study. ADAM12 levels were assayed in these serum samples. Serum levels of ADAM12 were converted to multiples of the median (MoM) after log-linear regression of concentration versus gestational age.RESULTS: Serum ADAM12 levels in women who developed preeclampsia during pregnancy had a mean log MoM of -0.066, which was significantly lower than the mean log MoM of -0.001 for ADAM12 levels observed in serum samples from women with normal pregnancy (P = .008). The mean log MoM was even lower in serum derived from preeclamptic women whose infant's weight at birth was less than 2,500 g (n = 27, mean log MoM of -0.120, P = .053).CONCLUSION: The maternal serum levels of ADAM12 are significantly lower during the first trimester in women who later develop preeclampsia during pregnancy when compared with levels in women with normal pregnancies. Because the secreted form of ADAM12 cleaves insulin-like growth factor binding protein (IGFBP)-3 and IGFBP-5, the IGF axis may play a role in preeclampsia. ADAM12 may be a useful early marker for preeclampsia.LEVEL OF EVIDENCE: II-2.

AB - OBJECTIVES: The secreted form of ADAM12 is a metalloprotease that may be involved in placental and fetal growth. We examined whether the concentration of ADAM12 in first-trimester maternal serum could be used as a marker for preeclampsia.METHODS: We developed a semiautomated, time-resolved, immunofluorometric assay for the quantification of ADAM12 in serum. The assay detected ADAM12 in a range of 78-1248 microg/L. Serum samples derived from women in the first trimester of a normal pregnancy (n = 324) and from women who later developed preeclampsia during pregnancy (n = 160) were obtained from the First Trimester Copenhagen Study. ADAM12 levels were assayed in these serum samples. Serum levels of ADAM12 were converted to multiples of the median (MoM) after log-linear regression of concentration versus gestational age.RESULTS: Serum ADAM12 levels in women who developed preeclampsia during pregnancy had a mean log MoM of -0.066, which was significantly lower than the mean log MoM of -0.001 for ADAM12 levels observed in serum samples from women with normal pregnancy (P = .008). The mean log MoM was even lower in serum derived from preeclamptic women whose infant's weight at birth was less than 2,500 g (n = 27, mean log MoM of -0.120, P = .053).CONCLUSION: The maternal serum levels of ADAM12 are significantly lower during the first trimester in women who later develop preeclampsia during pregnancy when compared with levels in women with normal pregnancies. Because the secreted form of ADAM12 cleaves insulin-like growth factor binding protein (IGFBP)-3 and IGFBP-5, the IGF axis may play a role in preeclampsia. ADAM12 may be a useful early marker for preeclampsia.LEVEL OF EVIDENCE: II-2.

KW - Adult

KW - Biomarkers

KW - Case-Control Studies

KW - Disintegrins

KW - Female

KW - Fluorescent Antibody Technique

KW - Humans

KW - Metalloproteases

KW - Pre-Eclampsia

KW - Predictive Value of Tests

KW - Pregnancy

KW - Pregnancy Trimester, First

KW - Probability

KW - Reference Values

KW - Risk Factors

KW - Sampling Studies

KW - Sensitivity and Specificity

KW - Comparative Study

KW - Journal Article

KW - Research Support, U.S. Gov't, Non-P.H.S.

U2 - 10.1097/01.AOG.0000165829.65319.65

DO - 10.1097/01.AOG.0000165829.65319.65

M3 - Journal article

C2 - 15994630

VL - 106

SP - 144

EP - 149

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 1

ER -

ID: 51786855